Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lymphoma 10Neutropenia 8Breast Neoplasms 8Leukemia, Myeloid, Acute 7Multiple Myeloma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Hematologic Neoplasms 4Febrile Neutropenia 4Leukemia, Monocytic, Acute 3Leukemia, Biphenotypic, Acute 3Hodgkin Disease 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Osteosarcoma 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Teratoma 1Solid Tumors 1Sarcoma, Myeloid 1Sarcoma, Clear Cell 1Rhabdoid Tumor 1Retinoblastoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1

Interventions

tislelizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1asciminib 1Topotecan 1Sirolimus 1SAR125844 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Tumors × pegylated granulocyte colony-stimulating factor × Clear all
NCT02805166 2016-06-17

PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Phase 4 Completed
420 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡